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Enhancing  bone  repair  is  the  key  process  which  facilitates  the  improvement  of  
fracture  healing  outcomes.  Despite  of  many  studies  regarding  osteogenesis  induction,  
Bone  morphogenetic  proteins-­2  (BMP-­2)  and  Platelet-­derived  growth  factor-­BB  (PDGF-­
BB)  are  still  the  only  two  the  Food  and  Drug  Administration  (FDA)-­approved  treatment1,  
2.  To  develop  potential  treatment  modalities,  it  is  essential  to  understand  the  role  of  
transcription  factors  in  fracture  healing  and  how  they  may  be  specifically  targeted  in  
preclinical  models  to  enhance  bone  regeneration.  While  the  Runt-­related  transcription  
factor  2  (Runx2)  is  known  to  play  a  crucial  role  in  osteoblastogenesis,  the  role  of  Runx3,  
a  homologue  of  Runx2,  in  osteoblastogenesis  remains  unclear.  Our  laboratory  has  
previously  reported  that  targeted  deletion  of  the  Runx3,  in  the  periosteum  resulted  in  
enhanced  fracture  healing  by  increased  bone  formation  and  biomechanical  properties  of  
the  fracture  callus  in  mutant  mice3.  Other  factors  participate  in  fracture  healing  including  
inflammatory  cytokines.  They  are  known  to  be  involved  in  fracture  healing  by  initiating  
the  repair  process  following  injury.  Recent  studies  demonstrated  that  one  of  the  most  
important  inflammatory  cytokines  controlling  fracture  healing  was  Interleukin  17  (IL-­17)4.  
It  was  previously  published  that  IL-­17  was  expressed  by  mesenchyme  cells,  periosteal  
cells,  and  chondrocytes  within  the  fracture  calluses  of  wild  type  mice5.  The  goal  of  this  
study  was  to  investigate  the  mechanism  of  how  Runx3  regulated  fracture  healing  and  
the  role  of  IL-­17  in  this  process  for  future  translation  into  a  preclinical  model  of  fracture  
healing.  The  hypothesis  was  that  conditional  knockout  of  Runx3  in  the  periosteum  
would  enhance  osteogenesis  through  upregulation  of  IL-­17  signaling.  To  investigate  this  
hypothesis,  Runx3  expression  was  conditionally  abrogated  in  limb  mesenchymal  
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progenitors.  Paired  related  homeobox  1  (Prx1)-­Cre  Runx3  F/F  mice,  which  lacked  Runx3  
activity  were  compared  to  control  mice  (Runx3  F/+)  with  100%  Runx3  activity.  Mid-­
diaphyseal  fracture  surgery  was  performed  on  12  week-­old  female  mice,  and  the  mice  
were  then  euthanized  at  7,  14,  and  21  days  post-­fracture  followed  by  harvesting  femurs  
for  molecular  and  histology  analysis.  The  absence  of  Runx3,  IL-­17A  and  IL-­17RA  were  
confirmed  by  RT-­PCR.  The  localized  expression  of  IL-­17A  and  the  receptor  IL-­17RA  
was  assessed  by  immunohistochemistry  to  identify  which  cells  were  responsible  for  the  
changes  in  expression.    




Fracture  healing  is  a  complex  process  which  involves  many  types  of  cells  to  
regenerate  new  bone.  To  improve  the  fracture  healing,  osteogenesis  is  the  key  process  
and  seminal  papers  have  been  published  regarding  this  process  over  the  years6.  
Osteogenesis  occurs  through  two  types  of  ossification:  intramembranous  ossification  
and  endochondral  ossification.  Intramembranous  ossification  occurs  mostly  in  the  flat  
bones  of  the  skull  forming  mesenchymal  stem  cell  differentiation  directly  to  osteoblasts,  
while  endochondral  ossification  process  occurs  when  mesenchymal  stem  cells  
differentiate  first  into  cartilage  following  by  a  subsequent  process  of  bone  replacement6,  
7.  To  explore  capable  modalities  in  order  to  accelerate  bone  regeneration  is  essentially  
critical  for  fracture  healing.  There  are  only  two  the  Food  and  Drug  Administration  (FDA)-­
approved  orthobiologic  treatment  modalities  to  induce  osteogenesis:  Bone  
morphogenetic  proteins  (BMPs)  and  Platelet-­derived  growth  factor-­BB  (PDGF-­BB).    
BMPs  induce  mesenchymal  stem  cells  to  differentiate  into  osteoblasts  to  form  
bone  in  targeted  tissues8.  In  2002,  the  BMP-­2  Evaluation  in  Surgery  for  Tibial  Trauma  
Study  Group  (BESTT)  published  the  results  from  a  450  patient  global  clinical  study  
showing  that  rhBMP-­2  loaded  collagen  sponges  greatly  benefited  patients  undergoing  
severe,  open  tibial  fracture  repair  surgeries  with  intramedullary  nail  fixation9.  This  result  
led  to  the  FDA’s  approval  of  Medtronic’s  INFUSE®.    However,  the  efficacy  remains  
unclear1,  10.  
PDGF-­BB  is  also  known  to  stimulate  osteoblast  or  osteoprogenitor  cell  activity  in  
favor  of  fracture  healing11.  However,  many  groups  have  raised  concerns  regarding  the  
efficacy  of  PDGF-­BB  resulting  in  conflicting  reports2.    
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Treatments  to  accelerate  bone  regeneration  are  critical  not  only  in  long  bone  
fracture  healing,  but  also  in  craniofacial  skeleton  such  as  congenital  and  acquired  facial  
bone  abnormality  and  traumatic  bone  fracture.  Currently  BMP-­2  has  been  used  for  
sinus  lift  and  alveolar  ridge  augmentation  and  PDGF-­BB  has  been  used  for  periodontal  
disease  and  bone  graft  for  the  implant  treatment.  
While  establishing  the  molecular  cues  that  govern  fracture  callus  formation  and  
remodeling  in  our  lab,  our  laboratory  previously  reported  that  targeted  deletion  of  the  
Runx3  (Runt  Related  Transcription  Factor  3),  a  homologue  of  the  osteogenic  master  
regulator  Runx2,  in  the  periosteum  resulted  in  enhanced  fracture  healing3.  Runx3  is  a  
transcription  factor,  known  to  be  related  to  cancer  suppression  due  to  reduction  of  the  
angiogenesis  and  also  found  in  growth  plate  during  endochondral  bone  formation12.  
Runx3  is  a  well-­established  key  regulator  of  chondrogenesis13,  14.  While  Runx2  plays  a  
crucial  role  in  osteoblastogenesis15,  16,  the  mechanism  of  Runx3  in  osteoblastogenesis  
remains  unclear.  Our  laboratory’s  study  indicated  that  the  enhanced  bone  healing  due  
to  Runx3  deletion  was  due  to  increasing  bone  formation  and  biomechanical  properties  
of  the  fracture  callus  in  mutant  mice.    
Moreover,  our  laboratory  found  that  the  Runx3  deletion  in  the  periosteal  cell  
populations  induced  angiogenic  as  well  as  osteogenic  differentiation  of  progenitor  cells  
within  the  healing  calluses.  This  was  evidenced  by  increasing  vessel  number  as  well  as  
increased  angiogenic  tube  formation  using  cells  harvested  from  fractured  limbs  of  
Runx3  conditional  knockout  mice  compared  to  control  littermates.  Angiogenesis  is  
essential  for  fracture  healing  to  make  blood  supply  from  existing  blood  vessels.  
Additionally,  colony  forming  unit  formation  was  also  increased  when  Runx3  conditional  
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knockout-­derived  periosteal  cells  were  cultured  in  osteogenic  media,  comparing  to  cells  
harvested  from  control  mice.    
Inflammatory  cytokines  are  known  to  be  involved  in  fracture  healing  by  initiating  
the  repair  process  following  injury.  They  are  immediately  secreted  after  injury  at  the  
injury  site  by  macrophages,  inflammatory  cells,  and  mesenchymal  origin  cells5.  
Interleukin  17  (IL-­17)  is  a  family  of  cytokines  composed  of  six  members17,  18.  IL-­17A  was  
cloned  in  a  T  cell  hybridoma  as  the  first  member  of  this  new  class  of  cytokines.  Other  
isoforms  homologous  to  IL-­17A  include  IL-­17B,  C,  D,  E  and  F5.    
IL-­17C,  D,  and  E  were  mainly  expressed  by  lymphocytes  such  as  T  cells  and  
Th17  cells.  However,  IL-­17A,  B  and  IL-­17F  are  expressed  by  progenitor  cells  in  fracture  
callus.  Recent  studies  demonstrated  that  IL-­17A  was  highly  induced  immediately  after  
bone  injury  and  promoted  bone  regeneration  by  accelerating  osteogenesis  via  its  effects  
on  injury-­associated  mesenchymal  cells4.  Kokubu  and  his  colleague  reported  that  IL-­
17B  was  localized  in  chondrocytes  of  both  the  growth  plate  and  the  fracture  callus  in  rat  
with  closed  fracture19.  Additionally,  IL-­17B  was  expressed  exclusively  in  the  
inflammatory  cartilage  and  neutralization  of  IL-­17B  significantly  suppressed  the  
progression  of  arthritis  and  bone  destruction  in  arthritis  mice20.  Despite  the  fact  that  both  
IL-­17A  and  F  bind  to  a  receptor  subunit  IL-­17RA17,  the  IL-­17F  binds  with  relatively  low  
affinity21  suggesting  that  IL-­17A  is  the  more  important  interaction.    
The  aim  of  this  study  is  to  investigate  the  underlying  mechanisms  of  Runx3  
control  of  fracture  healing,  and  to  see  whether  IL-­17  signaling  takes  in  part  in  the  
fracture  healing  and  which  cells  are  participating  the  IL-­17  signaling  pathway.  To  test  
this,  I  examined  expression  of  IL-­17A  and  the  receptor  IL-­17RA  expression  in  the  
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periosteal  cells  from  conditional  knockout  of  Runx3  mouse  to  demonstrate  whether  
specific  cells  express  high  levels  of  IL-­17A  to  recruit  progenitor  cells  into  osteogenic  









The  objective  of  this  study  was  to  test  whether  specific  cells  express  high  levels  of  IL-­





The  specific  aims  of  this  study  were:    
1.  To  examine  the  expression  of  IL-­17A  and  the  receptor  IL-­17RA  via  quantitative  RT-­
PCR  (qRT-­PCR)  from  fractured  limbs  of  Runx3  conditional  knockout  and  control  
littermates  at  various  stages  of  the  healing  process.  
  
2.  To  identify  which  cells  from  fractured  limbs  of  Runx3  conditional  knockout  and  control  
littermates  at  various  stages  of  the  healing  process  express  IL-­17A  and  the  receptor  IL-­




The  hypothesis  is  that  conditional  knockout  of  Runx3  in  the  periosteum  enhanced  





MATERIALS  AND  METHODS  
1.  Materials  
1.1  Animals  
Runx3  floxed  mice  (Runx3  F/F)  were  crossed  with  Prx1-­Cre  transgenic  mice  to  generate  
mice  in  which  Runx3  expression  is  conditionally  abrogated  in  limb  mesenchymal  
progenitors  (Prx1-­Cre  Runx3  F/F).  These  were  compared  with  control  mice  (Runx3  F/+)  
with  100%  Runx3  activity.  Twelve-­week  old  female  mice  were  divided  into  groups  and  a  
standard  mid-­diaphyseal  femoral  fracture  surgery  was  performed  on  mutant  and  control  
mice  as  described  previously22.  Following  the  surgery,  the  mice  were  euthanized  at  7,  




Six  week-­old  female  mice  were  sacrificed  to  harvest  fractured  and  intact  femurs  3  days  
after  the  fracture  surgery  (N=3  per  group).  Soft  tissue  and  muscle  were  cleaned  out  and  
ablate  to  flush  out  the  bone  marrow  cells.  The  periosteal  cells  were  scraped  from  the  
bone  under  sterile  conditions  and  cultured  in  hypoxia  for  1  week.  Cells  were  re-­plated  
into  12-­well  plates  and  osteogenic  media  was  added  after  24  hours  at  37oC,  5%  CO2  
until  day  7,  14  and  21  for  molecular  analysis.  
  
1.3  Antibodies  
Rabbit  anti-­mouse  polyclonal  IL-­17  (ab91649)  and  rabbit  anti-­mouse  polyclonal  IL-­17A  




2-­1  Molecular  analysis  of  the  callus  
Total  RNA  was  isolated  from  whole  calluses  (in  vivo)  and  periosteal  cells  (in  vitro)  from  
conditional  knockout  mice  and  control  littermates  (N=3  per  group  for  whole  calluses,  
N=5  per  group  for  periosteal  cells)  at  day  7,  14,  and  21  with  TRIzol  following  the  
manufacturer’s  protocol  (Invitrogen).  Briefly,  for  whole  calluses,  the  soft  tissue  was  
removed  from  femurs  and  bone  marrow  was  ablated.  Surgical  tools  were  used  to  isolate  
the  callus  from  the  rest  of  the  femur.  Only  the  callus  was  flash  frozen  in  liquid  nitrogen,  
and  subsequently  homogenized  in  TRizol.  For  the  intact  control,  the  whole  femur  was  
used.  After  DNase  I  (Invitrogen)  treatment,  cDNAs  were  synthesized  by  iScript  select  
cDNA  kit  following  the  manufacturer’s  protocol  (Bio-­Rad).  The  qRT-­PCR  was  performed  
using  SYBR  Green  Master  mix  (Applied  Biosciences)  and  StepOnePlus  real  time  PCR  
system  following  the  manufacturer’s  protocol  (Applied  Biosciences).  The  specific  
primers  used  were:  mouse  IL-­17A  (forward:  5’-­  GCT  CCA  GAA  GGC  CCT  CAG  ACT  -­
3’,  reverse:  5’-­  CCA  GCT  TTC  CCT  CCG  CAT  TGA  -­3’)23  and  IL-­17  RA  (forward:  5’-­  
AGT  GTT  TCC  TCT  ACC  CAG  CAC  -­3’,  reverse:  5’-­  GAA  AAC  CGC  CAC  CGC  TTA  C  -­
3’)24.  The  estimated  amount  of  the  gene  of  interest  was  normalized  to  Glyceraldehyde  
3-­phosphate  dehydrogenase  (GAPDH).    
 
2-­2  Immunohistochemistry  
The  femurs  were  harvested  from  conditional  knockout  mice  and  control  littermates  (N=5  
per  group)  at  day  7,  14,  and  21  after  the  fracture  surgery,  fixed  with  4%  
paraformaldehyde  and  embedded  in  paraffin.  The  sections  were  deparaffinized  and  
serially  rehydrated  by  incubation  3  times  in  Xylene  for  5  minutes,  2  times  in  100%  
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Ethanol  (EtOH)  for  10  minutes,  2  times  in  95%  EtOH  for  10  minutes,  2  times  in  H2O  for  
5  minutes  followed  PBS  for  5  minutes.  The  sections  were  then  next  antigen  retrieved  by  
incubation  in  sodium  citrate  buffer,  pH6.0  (SIGMA)  for  15  minutes  at  a  sub-­boiling  
temperature,  and  subsequently  removed  to  cool  on  the  bench  top  for  30  minutes.  After  
rinsing  in  H2O,  the  sections  were  incubated  with  3%  hydrogen  peroxide  (Thermo  Fisher  
Scientific)  for  10  minutes  to  quench  endogenous  peroxidase  activity  followed  by  
immunohistochemical  staining.  The  slides  were  then  incubated  with  5%  normal  goat  
serum  blocking  buffer  for  one  hour  at  room  temperature.  Subsequently,  the  slides  were  
incubated  with  rabbit  polyclonal  IL-­17A  (Abcam)  in  1:720  dilution  or  rabbit  polyclonal  IL-­
17RA  (Abcam)  in  1:200  dilution  at  4°C  overnight.  Then  peroxidase-­conjugated  rabbit  
SignalStain  Boost  IHC  Detection  Reagent  (Cell  Signaling)  was  used  as  secondary  
antibody  using  the  manufacturer’s  recommended  dilutions  and  incubating  for  30  
minutes  at  room  temperature.  Visualization  was  done  using  the  3,3-­diaminobenzidine  
(DAB)  substrate  kit  (Cell  Signaling)  following  the  manufacturer’s  protocol  followed  by  
coverslipping  with  VectaMount  AQ  (Vecta).  All  images  were  taken  at  4x,  10x,  20x  and  
40X  magnifications  using  an  Olympus  microscope.    
  
3.  Statistical  analysis  
All  data  were  reported  with  means  ±  standard  deviation  of  the  mean.  Parametric  data  
were  tested  using  a  student  T-­test  followed  by  an  F-­test  to  determine  normality  and  
differences  between  groups.  Statistical  significance  was  established  at  p<0.05.  




Expressions  of  IL-­17A  and  the  receptor  RA  were  increased  in  Prx1-­Cre  Runx3  F/F  
mice  and  the  induction  was  prominent  in  fractured  mice.  
   I  first  investigated  whether  IL-­17A  and  the  receptor  RA  were  expressed  in  whole  
callus  (in  vivo)  and  periosteal  cells  (in  vitro).  For  whole  callus,  qPCR  revealed  that  the  
expression  of  IL-­17A  was  increased  in  Prx1-­Cre  Runx3  F/F  groups,  whereas  IL-­17RA  did  
not  show  differences  in  the  intact  bone.  In  the  fractured  mice,  both  IL-­17A  and  IL-­17RA  
















Figure  1.  IL-­17A  and  IL-­17RA  were  increased  in  whole  callus  in  Prx1-­Cre    







For  periosteal  cell  culture,  qPCR  revealed  that  the  expressions  of  IL-­17A  and  IL-­














These  results  suggested  that  whole  callus  expressed  IL-­17A  and  IL-­17RA  and  that  the  
induction  was  significantly  pronounced  in  Prx1-­Cre  Runx3  F/F  mice.  
  
Hypertrophic  chondrocytes  and  periosteal  cells  were  responsible  for  Runx3  
conditional  knockout-­induced  expressions  of  IL-­17A  and  IL-­17RA  
qPCR  results  revealed  that  the  expression  of  IL-­17A  and  IL-­17RA  was  induced  in  
the  fractured  mice  with  targeted  deletion  of  Runx3  in  the  periosteum.  For  these  
experiments,  I  used  whole  calluses,  which  were  heterogeneous  subsets  involving  
  
  
Figure  2.  IL-­17A  and  IL-­17RA  were  increased  in  periosteal  cells  in  Prx1-­Cre  






chondrocytes,  osteoblasts,  osteoclasts,  mesenchymal  precursor  cells,  and  
hematopoietic  precursor  cells.    
To  determine  which  cells  were  responsible  for  the  induction  of  IL-­17A  and  IL-­
17RA  in  the  fracture,  I  employed  IHC  on  femur  sections  for  IL-­17A  and  IL-­17RA  at  day  7  
and  14  after  fracture  surgery.  Growth  plates  were  used  for  positive  control  against  the  
antibodies.  Figure  3  and  4  showed  that  IL-­17A  and  IL-­17RA  were  expressed  in  

















     
	  
	  
Figure  3.  IL-­17A  was  expressed  in  hypertrophic  chondrocytes  and  
periosteal  cells  in  Prx1-­Cre  Runx3  F/+  mice  at  day  7.  The  left  images  were  































Figure  5  and  6  showed  that  IL-­17A  and  IL-­17RA  were  expressed  in  hypertrophic  
chondrocytes  and  periosteal  cells  in  Prx1-­Cre  Runx3  F/F  mice.    
	  
	  
Figure  4.  IL-­17RA  was  expressed  in  hypertrophic  chondrocytes  and  
periosteal  cells  in  Prx1-­Cre  Runx3  F/+  mice  at  day  7.  The  left  images  






     
	  
	  
Figure  5.  IL-­17A  was  expressed  in  hypertrophic  chondrocytes  and  
periosteal  cells  in  Prx1-­Cre  Runx3  F/F  mice  at  day  7.  The  left  images  were  

























At  day  14,  hypertrophic  chondrocytes  were  not  observed  in  callus.  Thus,  I  examined  
sections  of  periosteal  cells  and  growth  plate.  Figure  7  and  8  showed  that  IL-­17A  and  IL-­




Figure  6.  IL-­17RA  was  expressed  in  hypertrophic  chondrocytes  and  
periosteal  cells  in  Prx1-­Cre  Runx3  F/F  mice  at  day  7.  The  left  images  were  





     
	  
	  
Figure  7.  IL-­17A  was  expressed  in  periosteal  cells  in  Prx1-­Cre  Runx3  F/+  





     
	  
  
Figure  8.  IL-­17RA  was  expressed  in  periosteal  cells  in  Prx1-­Cre  Runx3  F/+  






























Figure  9.  IL-­17A  was  expressed  in  periosteal  cells  in  Prx1-­Cre  Runx3  F/F  

















Figure  10.  IL-­17RA  was  expressed  in  periosteal  cells  in  Prx1-­Cre  Runx3  F/F  





Figure  9  and  10  showed  that  IL-­17A  and  IL-­17RA  were  expressed  in  periosteal  cells  in  
Prx1-­Cre  Runx3  F/F  mice.    Figure  11  and  12  showed  the  results  of  IHC  for  hypertrophic  
chondrocytes  and  periosteal  cells  at  day  7,  respectively.  Figure  13  showed  that  the  
result  of  IHC  for  periosteal  cells  at  day  14.  Both  IL-­17A  and  IL-­17RA  expressions  in  
hypertrophic  chondrocytes  were  significantly  enhanced  in  mice  targeted  deletion  of  
Runx3  in  periosteum  compared  with  control  mice  (Figure  11).    The  similar  trend  was  
observed  in  periosteum  at  day  7  (Figure  12)  and  day  14  (Figure  13).    
     
	  
Figure  11.  IL-­17A  and  IL-­17RA  were  significantly  increased  in  hypertrophic  








     
	  
Figure  12.  IL-­17A  and  IL-­17RA  were  increased  in  periosteal  cells  in  Prx1-­Cre  
































Figure  13.  IL-­17A  and  IL-­17RA  were  increased  in  periosteal  cells  in  Prx1-­Cre  








The  periosteum  consists  of  multipotent  progenitor  cells  and  they  play  crucial  
roles  following  bone  graft  and  in  musculoskeletal  pathologies.  Our  laboratory  previously  
reported  that  targeted  deletion  of  Runx3  in  the  periosteum  resulted  in  enhanced  fracture  
healing  and  that  the  enhanced  bone  healing  due  to  Runx3  deletion  was  due  to  
increasing  bone  formation  and  biomechanical  properties  of  the  fracture  callus  in  mutant  
mice3.    
Inflammatory  cytokines  are  known  to  be  involved  in  fracture  healing  by  initiating  
the  repair  process  following  injury.  They  are  secreted  immediately  after  injury  at  the  
injury  site  by  macrophages,  inflammatory  cells,  and  mesenchymal  origin  cells5.  Recent  
studies  demonstrated  that  IL-­17A  was  highly  induced  immediately  after  bone  injury  and  
promoted  bone  regeneration  by  accelerating  osteogenesis  via  its  effects  on  injury-­
associated  mesenchymal  cells4.  The  Runx  family  of  transcription  factors  has  
demonstrated  critical  functions  in  the  regulation  of  these  progenitors  through  IL-­17  
signaling  pathway  the  Runx  family  of  transcription  factors  has  demonstrated  critical  
functions  in  the  regulation  of  these  progenitors  through  IL-­17  signaling  pathway25,  26.    
Thus,  the  hypothesis  is  that  periosteal  cells,  following  conditional  knockout  of  
Runx3,  express  high  levels  of  IL-­17A  to  recruit  progenitor  cells  into  osteogenic  lineage  
resulting  in  bone  healing.  My  study  showed  that  the  expressions  of  IL-­17A  and  IL-­17RA  
were  induced  periosteal  cells  in  the  mice  with  targeted  deletion  of  Runx3  to  the  




There  is  controversy  regarding  IL-­17A  and  osteogenesis  and  bone  formation.  
Noh  reported  that  IL-­17A  increased  leptin  production  that  inhibits  adipogenesis  and  
promotes  osteogenesis  on  human  bone  marrow  derived  mesenchymal  stem  cells  via  
JAK/STAT  signaling27.  In  contrast,  there  is  a  paper  indicating  that  the  combination  of  IL-­
17A  and  TNF-­alpha  activated  osteoclasts  leading  to  bone  destruction  due  to  RANKL  
inhibition  and  Schnurri-­3  induction  in  human  mesenchymal  stem  cells26.  However,  they  
discussed  the  possibility  that  this  change  could  promote  ectopic  bone  formation  in  the  
absence  of  osteoclasts.  My  results  suggest  that  the  induction  of  IL-­17A  and  IL-­17RA  in  
callus  should  contribute  to  enhanced  bone  healing  in  Runx3  conditional  knockout  mice.    
Many  groups  have  reported  the  efficacy  of  IL-­17A  in  bone  formation  and  bone  
healing  in  mesenchymal  stem  cells27.  When  I  investigated  which  cells  played  a  key  role  
in  the  enhanced  bone  healing,  my  data  indicated  that  hypertrophic  chondrocytes  and  
periosteal  cells  were  responsible  for  the  Runx3  deletion-­induced  expressions  of  IL-­17A  
and  IL-­17RA.  Huang  reported  that  IL-­17  produced  by  T  cell  induced  proliferation  of  
human  bone  marrow-­derived  mesenchymal  stem  cells  depending  on  the  generation  of  
reactive  oxygen  species  (ROS)25.  IL-­17  signaling  may  promote  osteogenesis  and  
angiogenesis  to  lead  to  enhanced-­bone  repair  in  vivo.    
  




Understanding  the  pathways  underlying  Runx3  deletion  induced-­IL-­17  induction  
in  these  progenitor  cells  will  be  beneficial  to  the  translation  in  clinical  approaches.  
Currently,  there  are  only  two  FDA-­approved  modalities  for  orthobiologic  treatment.  
BMP-­2  has  been  used  for  sinus  lift  and  alveolar  ridge  augmentation  and  PDGF-­BB  has  
been  used  for  periodontal  disease  and  bone  graft  for  the  implant  treatment.  Mimicking  
these  effects  using  small  molecules  to  specifically  inhibit  Runx3  expression  locally  at  the  
fracture  site  could  be  a  new  treatment  modality  that  could  be  applied  to  oral  and  
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